Understand the source comparison
Comparison: Pe-22-28 Dosing Across Experimental Models
Depression behavior (FST, TST) 1 mg/kg Intraperitoneal 60 minutes Reduced immobility time, increased TREK-1 surface expression Gold standard dose. Most reproducible across labs and strains Ischemic stroke (MCAO model) 2–3 mg/kg Intraperitoneal or IV Immediatel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Depression behavior (FST, TST)
- 1 mg/kg
- Intraperitoneal
- 60 minutes
- Reduced immobility time, increased TREK-1 surface expression
- Gold standard dose. Most reproducible across labs and strains
- Ischemic stroke (MCAO model)
- 2–3 mg/kg
- Intraperitoneal or IV
- Immediately post-occlusion
- Reduced infarct volume, preserved neuronal viability
- Higher dose justified by competing pathology. Glutamate storm
- In vitro neuronal excitability
- 10–50 µM
- Direct bath application
- 15–30 minutes
- Hyperpolarization, reduced action potential frequency
- Concentration-dependent. Start at 10 µM and titrate upward
- Chronic pain (neuropathic model)
- 1 mg/kg daily × 7–14 days
- Subcutaneous
- Behavioral testing 24h after final dose
- Reduced mechanical allodynia via spinal TREK-1 activation
- Subcutaneous preferred for chronic dosing. Less handling stress
- Intracerebroventricular (ICV)
- 0.1–0.3 mg/kg
- ICV injection
- 30–45 minutes
- Direct CNS TREK-1 modulation, bypasses BBB
- Lowest dose due to direct CNS delivery. Reserve for BBB-limited contexts